Rubicon Research Limited
Kotak Mutual Fund increased its stake in Rubicon Research from 2.85% to 4.09%, purchasing 20,58,007 shares.
A pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated drug formulations across multiple therapeutic areas. Incorporated in 1999, the company specializes in creating specialized formulations that address specific medical needs in the Indian healthcare market. Its integrated operations span research and development, manufacturing of quality pharmaceuticals, and distribution. The company distinguishes itself through its focus on bringing innovative, differentiated solutions to patients and healthcare providers.
Wholly owned subsidiary of Kotak Mahindra Bank, one of India's leading private banks. Manages over Rs 4.5 lakh crore in AUM. MD Nilesh Shah is a fixture in Indian financial media and one of the most quoted fund managers in the country. Known for disciplined quality growth positioning and clear communication of investment rationale to investors.